Monalizumab plus durvalumab for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests whether adding monalizumab to durvalumab (two immune-targeting medicines) can improve outcomes in people with small cell lung cancer. You may be able to join if you have certain stage of small cell lung cancer and have not had the specific prior treatments the study allows.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and sign consent (and authorize release of health information).
- Have small cell lung cancer that is confirmed by biopsy or other tissue test, and fit the study’s stage and disease extent rules.
- Have adequate blood and organ test results from labs done within 28 days before enrollment (including white blood cells, hemoglobin, platelets, kidney function, and liver tests).
- Have an ECOG performance status that shows you can carry out daily activities (0–2 for one group, 0–1 for another).
- Have no recent major surgery (within 28 days), no active serious infection needing IV antibiotics, and no known allergy to study drugs.
- Follow pregnancy and contraception rules: if you can become pregnant or are male, you must use effective birth control; you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This study is testing a new combination of two immunotherapy drugs (adebrelimab and vunakizumab) plus chemotherapy for people with previously untreated extensive-stage small cell lung cancer. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This phase 2 trial studies whether durvalumab given with consolidation radiotherapy can help people with extensive-stage small cell lung cancer that has only a few metastases. It builds on initial chemotherapy and immunotherapy response, then targets the chest and limited metastatic spots with radiation.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.